NCT01936181View on ClinicalTrials.gov

A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

PHASE3CompletedINTERVENTIONAL

Enrollment

584

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2015

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Remicade (infliximab)

DRUG

SB2 (proposed biosimilar to infliximab)

Trial Locations (2)

8800

Investigational Site, Hristo Botev Str.

08661

Investigational Site, Santariskiu

All Listed Sponsors

lead

Samsung Bioepis Co., Ltd.

INDUSTRY

NCT01936181 - A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy | Biotech Hunter | Biotech Hunter